In 26 patients with hypothalamic obesity from brain tumors, semaglutide produced a mean weight loss of 13.4 kg (4.4 BMI points), with 58% losing over 10% and all but one patient losing weight — the first substantial evidence for effective pharmacotherapy in this notoriously treatment-resistant condition.
96% lost weightAll but one of 26 patients with hypothalamic obesity lost weight on semaglutide — remarkable for a condition where diet, exercise, and previous drugs have consistently failed
What the researchers found
26 patients with hypothalamic obesity treated with semaglutide (median dose 1.6 mg). Mean weight loss: 13.4 kg (95% CI: 10.3-16.5 kg, p<0.001). Mean BMI reduction: 4.4 kg/m² (95% CI: 3.4-5.4, p<0.001). 25/26 patients (96%) lost weight. 15 patients (58%) lost >10% body weight. 2 patients (8%) lost >20%.
Why it matters
Hypothalamic obesity is one of the most devastating complications of brain tumors and their treatment. Until now, no pharmacotherapy has shown meaningful benefit. This study provides the first real evidence that GLP-1 drugs can work even when the brain's normal appetite circuits are destroyed — suggesting they act through alternative neural pathways.
The numbers in context
Patients tracked at the Department of Endocrinology, Rigshospitalet. Weight data collected before and after semaglutide initiation.
How the study worked
Real-world retrospective cohort study at Rigshospitalet, Copenhagen (September 2020 to November 2023). 26 patients with acquired hypothalamic obesity (15 females, median age 52, range 18-65). Semaglutide at median dose 1.6 mg (range 0.5-2.5 mg). Weight tracked before and during treatment.
Who was studied
Patients with hypothalamic obesity from hypothalamic-region tumors
What this study cannot tell us
Small cohort (26 patients). Retrospective design without control group. Variable follow-up duration. No information on diet/exercise changes during treatment. The heterogeneous nature of hypothalamic injury (different tumors, different surgical approaches) limits generalizability. Long-term weight stability after treatment not assessed.
How to read the evidence
Rated preliminary: small uncontrolled retrospective cohort. However, the consistent response in a notoriously treatment-resistant population makes the signal compelling.
When this study was published
Published in 2024. Covers 3+ years of treatment experience (2020-2023) at a major European endocrinology center.
The bigger picture
If semaglutide works when the hypothalamic appetite centers are destroyed, it tells us something fundamental about how GLP-1 drugs cause weight loss — they must be acting through brainstem, hindbrain, or other pathways beyond the hypothalamus. This has implications for understanding GLP-1 drug mechanisms in all patients.
Questions still open
- Which neural pathways does semaglutide use when hypothalamic circuits are destroyed?
- Is the weight loss sustainable long-term, or will hypothalamic obesity recur if semaglutide is stopped?
- Would higher doses or dual agonists (tirzepatide) produce even better results in this population?
Common questions
What is hypothalamic obesity and why is it so hard to treat?
How does semaglutide work if the brain's appetite center is damaged?
Read the original research
Semaglutide treatment of hypothalamic obesity - a real-life data study.
Pituitary, 27(5), 685-692
Citation
Svendstrup, Mathilde; Rasmussen, Aase Krogh; Kistorp, Caroline; Klose, Marianne; Andreassen, Mikkel. (2024). Semaglutide treatment of hypothalamic obesity - a real-life data study.. Pituitary, 27(5), 685-692. https://doi.org/10.1007/s11102-024-01429-5